This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients. * Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples. * Correlation analysis of KRAS mutation results with clinical data. Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel. * Gene panel composition for pancreatic cancer therapeutic target determination and monitoring. * A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients. * Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Study Type
OBSERVATIONAL
Enrollment
420
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
Goyang-si, Gyeonggi-do, South Korea
Clinical applicability of KRAS mutations
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
Discovery of biomarkers through ctDNA panel
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
Time frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.